Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2001

View Archived Issues

Cetiedil analogue with increased potency for blocking RBC Ca2+-activated K+ permeability

Nastech licenses European rights to intranasal morphine

New minimally invasive biopsy technology for breast cancer receives FDA clearance

FDA approves test that screens patients for InterStim Therapy for Urinary Control

Companies collaborate on novel herpes treatment

Orally active inhibitor of both thromboxane synthase and 5-LO presented at ERS meeting

Targeted antisense therapy for asthma developed in China

NCX-1015 and prednisolone have different profiles in experimental models

Sch-351591 described as promising candidate for respiratory disorders in Edinburgh

Antinociceptive effects reported for HCT-1026 in rat model of cystitis

Selective cdk2 inhibitor induces apoptosis, inhibits proliferation in human tumor cells

DA-8159 in clinical testing for erectile dysfunction

First NDA filing for PhotoCure in U.S.

Fixed antimalarial combination of artemether and lumefantrine now on the market in Germany

Another major European launch for enzyme therapy for use in tumor lysis syndrome

Clinical results with efalizumab for asthma reported at ERS meeting

Extensive preclinical and clinical coverage of ciclesonide at ERS

Safer hypoglycemic agents in the ADIR pipeline

New PARP inhibitors described in recent patent by BASF

MMP inhibitor developed at Banyu induces apoptosis in human leukemia cells

Boehringer Ingelheim presents new AMPA receptor modulators and potential uses thereof

Recent patents cover Pfizer's newest PDE4 inhibitors

Protein kinase inhibitors for cancer, cardiovascular disorders discovered at Vertex

Orally active taxane derivatives under study at BMS

New Novartis compounds with potential in osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...